Vessel co-option in cancer (Q91997710)

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Relation of neovascularisation to metastasis of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Correlation of Vascular Endothelial Growth Factor Expression and Microvessel Density in Cervical Intraepithelial Neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiogenesis in primary lung cancer and lung secondaries

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Antiangiogenic therapy in oncology: current status and future directions

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Systemic treatment of renal cell cancer: A comprehensive review

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Reappraising antiangiogenic therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Therapeutic targeting of the angiopoietin-TIE pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Evidence Showing That Tumors Can Grow Without Angiogenesis and Can Switch Between Angiogenic and Nonangiogenic Phenotypes

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Hostile takeover: how tumours hijack pre-existing vascular environments to thrive

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiotropism, pericytic mimicry and extravascular migratory metastasis in melanoma: an alternative to intravascular cancer dissemination

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

John Hunter and the origin of the term "angiogenesis".

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

HETEROLOGOUS TRANSPLANTATION OF MAMMALIAN TUMORS : I. THE TRANSFER OF RABBIT TUMORS TO ALIEN SPECIES.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Judah Folkman, a pioneer in the study of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Mechanism of tumour vascularization in experimental lung metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Expression of vascular endothelial growth factor in human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Patterns of angiogenesis in nonsmall-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vascular endothelial growth factor-A determines detectability of experimental melanoma brain metastasis in GD-DTPA-enhanced MRI.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Different growth patterns of non-small cell lung cancer represent distinct biologic subtypes

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiogenesis and extracellular matrix remodelling in bronchioloalveolar carcinomas: distinctive patterns in mucinous and non-mucinous tumours

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Peripheral squamous cell carcinoma of lung: patterns of growth with particular focus on airspace filling

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Is nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructions

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Prognostic Impact of Intra-alveolar Tumor Spread in Pulmonary Adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Non-angiogenic tumours and their influence on cancer biology.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Why some tumours trigger neovascularisation and others don't: the story thus far.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Immunohistochemical evidence that lung carcinomas grow on alveolar basement membranes

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Primary and Metastatic Bronchiolo-Alveolar Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Solitary pulmonary metastasis from malignant melanoma of the bulbar conjunctiva presenting as a pulmonary ground glass nodule: Report of a case

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vascularization of small hepatocellular carcinomas: correlation with differentiation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Dynamic computed tomography during arterial portography: the most sensitive examination for small hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Observation of microvascular casts of human hepatocellular carcinoma by scanning electron microscopy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

How to Differentiate Borderline Hepatic Nodules in Hepatocarcinogenesis: Emphasis on Imaging Diagnosis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Sinusoidal capillarization in small hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilin-2 expression in peri-tumourous liver correlates with increased survival.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Histologic growth pattern of hepatocellular carcinoma: relationship to orcein (hepatitis B surface antigen)-positive cells in cancer tissue

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Pathology of small hepatocellular carcinoma. A proposal for a new gross classification

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

The histological growth pattern of colorectal cancer liver metastases has prognostic value

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

International consensus guidelines for scoring the histopathological growth patterns of liver metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiogenesis of liver metastases: role of sinusoidal endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Growth patterns of colorectal cancer liver metastases and their impact on prognosis: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Structural analysis of oval-cell-mediated liver regeneration in rats.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Cell competition leads to a high level of normal liver reconstitution by transplanted fetal liver stem/progenitor cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

The morphological growth patterns of colorectal liver metastases are prognostic for overall survival

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Rapid liver enlargement and hepatic failure secondary to radiographic occult tumor invasion: two case reports and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Diffuse intra-sinusoidal metastatic carcinoma of the liver

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Patterns of liver infiltration in lymphoproliferative disease.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Recruitment mechanisms of primary and malignant B cells to the human liver

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Imaging of Angiotropism/Vascular Co-Option in a Murine Model of Brain Melanoma: Implications for Melanoma Progression along Extravascular Pathways.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Leukaemia hijacks a neural mechanism to invade the central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiogenesis in brain tumours

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Gliomatosis cerebri: quantitative proof of vessel recruitment by cooptation instead of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Diffuse glioma growth: a guerilla war

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Glioblastoma: a pathogenic crosstalk between tumor cells and pericytes

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Invasion of experimental rat brain tumor: early morphological changes following microinjection of C6 glioma cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Pericytic-like angiotropism of glioma and melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiogenesis-independent tumor growth mediated by stem-like cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Bradykinin promotes the chemotactic invasion of primary brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Invasion patterns in brain metastases of solid cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Real-time imaging reveals the single steps of brain metastasis formation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiotropism in primary cutaneous melanoma with brain metastasis: a study of 20 cases

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Lack of angiogenesis in experimental brain metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Serpins promote cancer cell survival and vascular co-option in brain metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

The vascular basement membrane as "soil" in brain metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

A novel concept of glomeruloid body formation in experimental cerebral metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Ultrastructural and immunohistochemical studies of the periendothelial matrix in human melanoma: evidence for an amorphous matrix containing laminin

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumour spread

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiotropism is an independent predictor of local recurrence and in-transit metastasis in primary cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiogenesis is redundant for tumour growth in lymph node metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Lack of angiogenesis in lymph node metastases of carcinomas is growth pattern-dependent

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Prospects for vasculature reorganization in sentinel lymph nodes

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vascular co-option in lung cancer metastatic to the eye after treatment with bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiomorphology of the human renal clear cell carcinoma. A light and scanning electron microscopic study

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Growth pattern, an important pathologic prognostic parameter for clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Hijacking the vasculature in ccRCC--co-option, remodelling and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

The perivascular niche regulates breast tumour dormancy.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Inhibition of Endosteal Vascular Niche Remodeling Rescues Hematopoietic Stem Cell Loss in AML.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Hypoxia: a key regulator of angiogenesis in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Histologic growth patterns of metastatic carcinomas of the liver

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

'Nodule-in-nodule' appearance in hepatocellular carcinoma: its significance as a morphologic marker of dedifferentiation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Mechanisms of vascularization in murine models of primary and metastatic tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Histologic type-specific vascular patterns in rat tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

The percentage of lepidic growth is an independent prognostic factor in invasive adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Intertumor heterogeneity in vascularity and invasiveness of artificial melanoma brain metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Small adenocarcinoma of the lung. Histologic characteristics and prognosis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Evaluation of radiological and pathological prognostic factors in surgically-treated patients with bronchoalveolar carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Prognostic value of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Immunocytochemical markers in stage I lung cancer: relevance to prognosis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Prognostic value of nonangiogenic and angiogenic growth patterns in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Growth pattern of colorectal liver metastasis as a marker of recurrence risk

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Angiotropism in cutaneous melanoma: a prognostic factor strongly predicting risk for metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Prognosis according to histochemical analysis of liver metastases removed at liver resection

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Antiangiogenic Therapy for Glioblastoma: Complex Biology and Complicated Results.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

DNA damage-mediated induction of a chemoresistant niche

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Hypoxia and radiation therapy: past history, ongoing research, and future promise

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Investigating intracranial tumour growth patterns with multiparametric MRI incorporating Gd-DTPA and USPIO-enhanced imaging

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Phase contrast MRI is an early marker of micrometastatic breast cancer development in the rat brain

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Depiction of portal supply in early hepatocellular carcinoma and dysplastic nodule: value of pure arterial ultrasound imaging in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Perilesional enhancement of hepatic metastases: correlation between MR imaging and histopathologic findings-initial observations

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Emerging concepts in liquid biopsies

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

β1 integrin: Critical path to antiangiogenic therapy resistance and beyond

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Genes expressed in human tumor endothelium

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Vascular zip codes in angiogenesis and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

An overview of the influence of therapeutic ultrasound exposures on the vasculature: high intensity ultrasound and microbubble-mediated bioeffects

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Targeting tumor vasculature with an oncolytic virus

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Role of arterial occlusion in pulmonary scar cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

CELLULAR CHANGES IN THE VICINITY OF METASTATIC CARCINOMA, OBSERVED BY LIGHT AND ELECTRON MICROSCOPY

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

The vascular supply of tumours with special reference to the capillary angioarchitekture

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Molecular mechanisms and clinical applications of angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Mechanisms of glioma-associated neovascularization

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Distinct contributions of angiogenesis and vascular co-option during the initiation of primary microtumors and micrometastases

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

The Demise of the Term Bronchioloalveolar Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

A randomized trial of bevacizumab for newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Improved survival with bevacizumab in advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1038%2FS41571-019-0181-9

7 January 2021